Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 22, 2023
A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis
Ruth Dobson, David Holden, Nicola Vickaryous, et al.
Pain Medicine (Malden, Mass.)
|
February 9, 2021
Opioid Overdose Risk in Patients Returning to the Emergency Department for Pain
Sophia Sheikh, Ashley Booth-Norse, David Holden, et al.
Acta Crystallographica. Section D, Biological Crystallography
|
May 31, 2002
The three-dimensional structure of calcium-depleted human C-reactive protein from perfectly twinned crystals
Mohamed A M Ramadan, Annette K Shrive, David Holden, et al.
Microbiology (Reading, England)
|
February 7, 2001
Characterization of the Streptococcus pneumoniae NADH oxidase that is required for infection
Jun Yu, Alexander P Bryant, Andrea Marra, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
August 23, 2020
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
Saúl Reyes, Ide Smets, David Holden, et al.
Annals of Intensive Care
|
May 21, 2021
Lipid and lipoprotein predictors of functional outcomes and long-term mortality after surgical sepsis
Faheem W Guirgis, Christiaan Leeuwenburgh, Lyle Moldawer, et al.
Methods in Enzymology
|
June 29, 2010
Real-time DNA sequencing from single polymerase molecules
Jonas Korlach, Keith P Bjornson, Bidhan P Chaudhuri, et al.
Multiple Sclerosis and Related Disorders
|
December 6, 2021
Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study
Ide Smets, David Holden, Lucia Bianchi, et al.
Multiple Sclerosis and Related Disorders
|
July 11, 2018
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study
Julian Gold, Monica Marta, Ute C Meier, et al.
Clinical Immunology (Orlando, Fla.)
|
October 20, 2024
Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells
Francesca Ammoscato, Mohammad Wafa, Justyna Skonieczna, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 22, 2023
A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis
Ruth Dobson, David Holden, Nicola Vickaryous, et al.
Pain Medicine (Malden, Mass.)
|
February 9, 2021
Opioid Overdose Risk in Patients Returning to the Emergency Department for Pain
Sophia Sheikh, Ashley Booth-Norse, David Holden, et al.
Acta Crystallographica. Section D, Biological Crystallography
|
May 31, 2002
The three-dimensional structure of calcium-depleted human C-reactive protein from perfectly twinned crystals
Mohamed A M Ramadan, Annette K Shrive, David Holden, et al.
Microbiology (Reading, England)
|
February 7, 2001
Characterization of the Streptococcus pneumoniae NADH oxidase that is required for infection
Jun Yu, Alexander P Bryant, Andrea Marra, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
August 23, 2020
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
Saúl Reyes, Ide Smets, David Holden, et al.
Annals of Intensive Care
|
May 21, 2021
Lipid and lipoprotein predictors of functional outcomes and long-term mortality after surgical sepsis
Faheem W Guirgis, Christiaan Leeuwenburgh, Lyle Moldawer, et al.
Methods in Enzymology
|
June 29, 2010
Real-time DNA sequencing from single polymerase molecules
Jonas Korlach, Keith P Bjornson, Bidhan P Chaudhuri, et al.
Multiple Sclerosis and Related Disorders
|
December 6, 2021
Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study
Ide Smets, David Holden, Lucia Bianchi, et al.
Multiple Sclerosis and Related Disorders
|
July 11, 2018
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study
Julian Gold, Monica Marta, Ute C Meier, et al.
Clinical Immunology (Orlando, Fla.)
|
October 20, 2024
Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells
Francesca Ammoscato, Mohammad Wafa, Justyna Skonieczna, et al.
Page
of 3